Novel acaricidally active tetrazine derivatives

Abstract: The invention relates to novel tetrazine derivatives of the formula (I), wherein X means fluorine, chlorine or bromine; and Y stands for hydrogen or fluorine, as well as to a process for the preparation thereof. Furthermore, the invention relates to compositions containing the above compounds as well as to a process for the preparation thereof. The compounds and compositions according to the invention have acaricidal, larvicidal and ovicidal effects. The advantage of the active compounds of the invention consists in that their effect is translaminar; in addition, they also show a systemic effect. They are particularly useful for combatting mites belonging to the Tetranychidae family of pests.

Description: The invention relates to novel tetrazine derivatives and a process for their preparation. Furthermore, the invention relates to acaricidal compositions containing the novel compounds as well as to the preparation and use of these compositions. The compounds of the invention are effective against mites, their larvae and especially their eggs. It is known that phytophagous mites are potentially the most important pests damaging the cultivated food-, industrial and ornamental plants as well as stored crops whereas ectoparasitic mites are severely dangerous from the viewpoint of public and veterinary hygiene. The loss caused by phytophagous mites and the importance of protection against them has abruptly been enhanced. This can essentially be attributed to two reasons: 1) The predators and parasites maintaining the mite populations below the threshold value of loss were thinned by the use of non-selective insecticides. 2) Due to the short generation time and their adapta bility, mites develop resistance within a relatively short period. Typical representatives of harmful mite species in question are: spider mite (Tetranychus urticae), itch-mite (Psoroptes cuniculi), red spider mite (Tetranychus cinnabarinus) and other species hereinafter listed in detail. Due to the increasing loss caused by mites, the development of highly effective, specific acaricides is of increasing interest. For this purpose, a high number of tetrazine derivatives have been synthesized by various research groups (see EP-A-5912, EP-A-29657 and EP-A-248,466 as well as HU 184,684). A series of 1,2,4,5-tetrazines has been synthesized and screened for acaricidal activity by P.J. Brooker et al., Pestic. Sci. 18 (1987) 179-190, among others 3,6-bis(2-chlorophenyl)-1,2,4,5-tetrazine or 3,6-bis (2-fluorophenyl)-1,2,4,5-tetrazine. In the EP-A-5912 several 3,6-bis(2-halophenyl)-1,2,4,5-tetrazines and 3,6-bis(2-halophenyl)-1,2-dihydro-1,2,4,5-tetrazines are disclosed, wherein the halogens, being the same or different for each compound, may be fluorine, chlorine or bromine. In EP-A-29657 a number of other 3,6-bis(2-halophenyl)-1,2,4,5-tetrazines and 3-(2,5-dichlorophenyl)-6-(2-chlorophenyl)-1,2,4,5-tetrazine, too, are described. From these compounds 3,6-bis(2-chlorophenyl)-1,2,4,5-tetrazine described in EP-A-5912 became commercially available under the trade name Apollo® (clofentezine; Pesticide Manual 1987, page 188). Being inactive against adult individuals and nymphs as motile development forms of mites, clofentezine is a selectively ovicidal compound. Regarding its advantageous properties, it should be mentioned that it is selective (due to its novel mechanism of action), highly active, non-toxic to warm-blooded species, has a prolonged action and is essentially safe for beneficial insects [Entomophaga 36 , pages 55-67 (1991)]. However, despite of many advantages of clofentezine, it is also known that it has a contact effect, is not absorbed through the leaf and consequently, it is ineffective against the unsprayed mite eggs being present e.g. on the non-treated surface of the leaf [Pestic. Sci. 18 , pages 179-190 (1987)]. The complete coveredness of the foliage is not assured practically in any case. Thus, compositions which can penetrate into the plant and be then translocated to the proper site, are only effective against pests living in a hidden manner of life or residing in a rest, immobile state at a safe site. Based on the above knowledge, the object of this invention is to provide ovicidally active acaricides which, while possessing the favourable properties of clofentezine, exert an additional excellent translaminar effect. This object is achieved according to the independent claims. The dependent claims relate to prefered embodiments. Thus, a high number of new tetrazine derivatives not described up to the present have been synthesized and the influence of modifications of the molecular structure on the translaminar acaricidal effect, especially the ovicidal effect, was studied. It has been found that 3,6-diphenyl-1,2,4,5-tetrazine derivatives of the formula (I), wherein X means fluorine, chlorine or bromine; and Y stands for fluorine or hydrogen, substituted by fluorine, chlorine or bromine in ortho-position and containing fluorine or hydrogen in ortho'-position of the 3-phenyl group as well as substituted by fluorine both in ortho- and ortho'-positions of the 6-phenyl group, possess an essentially new property, i.e. translaminar activity in addition to their stronger, inherent ovicidal effect. This is of decisive importance for their practical utilization. Preferred representatives of the compounds of formula (I) are 3-(2-bromophenyl)-6-(2,6-difluorophenyl)-1,2,4,5-tetrazine, 3,6-bis(2,6-difluorophenyl)-1,2,4,5-tetrazine and 3-(2-chlorophenyl)-6-(2,6-difluorophenyl)-1,2,4,5-tetrazine as well as their tautomers. In addition, the compounds of formula (I) according to the invention exert also a systemic effect namely, they act after being absorbed through the root and translocated into the sprout. The advantages of the compounds of formula (I) of the present invention may be summarized as follows (but without any limitation thereto). 1) Their higher efficiency provides a lower specific dose and decreased environmental load. 2) Due to their excellent translaminar activity, the mite eggs escaping the spraying are also killed. 3) Due to their excellent transovarian effect, sterile eggs develop in the feeding females. 4) Their systemic action results in a significant broadening of the spectrum of effects and consequently of the scope of their applicability. 5) Due to their longer duration of effect and transovarian activity, the times of optimum protection can be determined more easily from a technological point of view. 6) Due to their transovarian effect, they are useful for developing environmentally less harmful processes of plant protection (e.g. protection after harvesting). The compounds of formula (I) or the compositions containing them, respectively, give excellent results against Tetranychus urticae, Tetranychus cinnabarinus, Tetranychus viennensis, Panonychus ulmi, Bryobia and Schizotetranychus species belonging to the Tetranychus family; as well as against many species belonging to the Eriophydae and Tenuipalpidae families; furthermore, they can be employed with good results in all areas endangered by a loss caused by mites, e.g. in the protection of stores or in the public and veterinary hygiene. From these latter ones, the more important pests are exemplified by the Boophilus, Dermacentor, Ixodes, Rhipicephalus, Psoroptes and Sarcoptes species. The compounds of formula (I) according to the invention can be transformed to compositions by using processes commonly known for plant-protective, pesticidal and veterinary hygienic formulations which can equally be applied onto plants, stored crops, soil and farm animals. These compounds are soluble e.g. in water-immiscible solvents such as high-boiling hydrocarbons (e.g. xylene) as vehicles containing suitable emulsifying agents; thus, after being added to water, these compositions behave as self-emulsifying oils. Alternatively, the substituted tetrazines may be mixed with a wetting agent and optionally with a solid carrier to obtain wettable powders that are soluble or dispersible in water or mixed with solid carriers, too, to prepare solid products. An aqueous suspension concentrate may also be prepared by grinding the active ingredient together with water, wetting and suspending agent. The surfactant may be ionic, anionic or cationic in its character. Preferable surfactants are e.g. ethoxylated fatty alcohol sulfates, ligninsulfonates, alkylaryl sulfonates, salts of sulfonated naphthalene/formaldehyde condensates, salts of sulfonated phenol/formaldehyde condensates, sodium oleyl-N-methyltauride, dialkyl sulfosuccinates, alkylphenyl ethoxylates and fatty alkyl ethoxylates. In addition to the substituted tetrazines, the compositions of the invention may contain also other active ingredients, e.g. insecticidal, acaricidal, ovicidal, bactericidal or fungicidal agents. The compositions containing the active ingredients of formula (I) may be used at any site infected by mites or where the eggs or larvae of mites are present or expected to occur. The compositions according to the invention may be used e.g. on plants, animals or the soil. Plants which can be treated with the compositions according to the invention are e.g.: sorts of cereals, plantations and ornamental plants such as cotton, tobacco, rice, fruit-trees and cereals, e.g. apple-tree, pear-tree, apricot-tree, peach-tree, citrus sorts, maize, barley or wheat, bean, sugar-beet, potato or carrot; or greenhouse plants and crops, e.g. pepper, tomato, cucumber, melon and strawberry. For the various uses, the compositions containing the compounds of formula (I) may be employed in various amounts. Thus, 17 to 1120 g/hectare (g/ha) amounts of a composition may be applied onto the plant; or concentrations of 1 to 2000 ppm, preferably 100 to 1000 ppm, especially 35 to 280 g/ha of active agent may be used for killing the pests damaging the plants. The novel compounds of formula (I) according to the invention can be prepared according to methods known in the art as described in detail in the published European patent application No. 5912. Thus, the compounds of formula (I) wherein X means fluorine, chlorine or bromine; and Y stands for fluorine or hydrogen, are prepared by a) reacting a substituted bis-azine of formula (II) wherein X and Y are as defined above, and A as well as B stand for cleavable groups, with hydrazine of formula (III), H 2 N - NH 2 or the hydrate thereof, then oxidizing the obtained 3,6-disubstituted-1,2-dihydro-1,2,4,5-tetrazine of formula (IV), wherein X and Y are as defined above; or b) reacting an 1,3,4-thiadiazole derivative of formula (V), wherein X and Y are as defined above, with an alkyl sulfate of formula (VII) R 2 SO 4 wherein R represents a C 1-4 alkyl group, then transforming the obtained thiadiazolium salt of formula (VI), wherein X, Y and R are as defined above, with hydrazine of the formula (III) or the hydrate thereof, and subsequently oxidizing the resulting 3,6-di-substituted-1,2-dihydro-1,2,4,5-tetrazine of formula (IV), wherein X and Y are as defined above; or c) oxidizing a 3,6-disubstituted-1,2-dihydro-1,2,4,5-tetrazine derivative of the formula (IV), wherein X and Y are as defined above. The preparation of the starting compounds of formulae (II) and (V) from commercially available products is described in the published European patent application No. 5912. The synthesis of the compound of formula (I) as well as substances disclosed in EP-A-5912 used as reference substances is illustrated in detail in the following non-limiting Examples. Further Examples show the preparation of compositions from compounds of the formula (I). The biological activity of compounds of formula (I) according to the invention is demonstrated in the Biological Examples. The Examples are only illustrative without any limitation thereto. The indicated percentages are by mass. Chemical Examples Example 1 3-(2-Bromophenyl)-6-(2,6-difluorophenyl)-1,2,4,5--tetrazine a.) N-(2-Bromobenzoyl)-N'-(2,6-difluorobenzoyl)hydrazine 0.94 g (1.05 equivalent) of 2,6-difluorobenzoyl chloride is added dropwise to a mixture containing 1.1 g of (2-bromobenzoyl)hydrazine, 3 ml of dimethylformamide and 0.5 ml of pyridine under cooling. The suspension obtained is stirred at room temperature for 30 minutes, then poured into water. The solid precipitate is separated by filtration and dried to give the aimed product as white crystals in a yield of 1.35 g. Analysis: C(9%) H(%) N(%) BR(%) F(%) calculated: 47.35 2.55; 7.89 22.43 10.70 found: 47.38 2.41 7.88 22.50 10.40 1 H-NMR (MeOD), ppm 7.07-7.12, 2H, t, 3- and 5-protons of Ar(2,6-F 2 ) 7.54, 1H, m, 4-proton of Ar(2,6-F 2 ) 7.68, 1H, dd, 3-proton of Ar(2-Br) 7.63, 1H, dd, 6-proton of Ar(2-Br) 7.39, 1H, dt, 4-proton of Ar(2-Br) 7.46, 1H, dt, 5-proton of Ar(2-Br) 13 C-NMR (MeOD), ppm Ar (2,6-F 2 )-CO-NH 168.93 Ar (2-Br)-CONH 161.734 Ar (2,6-F 2 ): 1 114 Ar (2-Br): 1 137.55 2 , 6 162.54, 16.03 2 120.07 3 , 5 112.81, 113.06 3 134.40 4 133.7 4 128.86 5 130.50 6 132.85 b.) N-[Chloro-(2-bromophenyl)methylene]-N'-[chloro-(2,6-difluorophenyl)methylene]hydrazine To a solution of 3.95 g of phosphorus pentachloride in 10 ml of carbon tetrachloride 1.35 g of product prepared in the preceeding step a.) are portionwise added during 5 minutes under boiling. After boiling the reaction mixture under reflux for 8 hours and evaporation of the excess of the solvent and phosphorous pentachloride, the residue is poured into 10 % sodium hydroxide solution while cooling and then extracted with ethyl acetate. The organic phase is washed with water until neutral, dried over anhydrous magnesium sulfate and evaporated. The crude product is purified by column chromatography to give 0.96 g of the title product as snow-white crystals. 1 H-NMR (CDCl 3 ), ppm 7.00-7.06, 2H, t, 3- and 5-protons of Ar(2,6-F 2 ) 7.35-7.50, 4H, m, 4,5,6-protons of Ar(2-Br) and 4-proton of Ar(2,6-F 2 ) 7.61-7.72, 1H, dd, 3-proton of Ar(2-Br) 13 C-NMR (CDCl 3 ), ppm Ar(2-Br): 1 132.51 Ar(2,6-F 2 ): 1 113.61 2 121.48 2,6 158.85, 164.40 3 132.61 3,5 111.90, 112.14 4 130.87 4 132.61 5 127.48 6 133.76 c.) 3-(2-Bromophenyl)-6-(2,6-difluorophenyl)-1,2-di - hydro-1,2,4,5-tetrazine To a solution containing 0.96 g of N-[chloro-(2-bromophenyl)methylene]-N'-[chloro-(2,6-difluorophenyl)methylene]hydrazine [prepared in the preceeding step b.)] in 20 ml of tetrahydrofuran, 0.62 g of hydrazine hydrate is slowly added at 40 °C temperature. The precipitate is filtered, washed with water and dried to obtain 0.62 g of the title product as yellow crystals. d.) 3-(2-Bromophenyl)-6-(2,6-difluorophenyl)-1,2,4,5-tetrazine A solution of 0.26 g of sodium nitrite in 1 ml of water is dropwise added to a solution containing 0.62 g of 3-(2-bromophenyl)-6-(2,6-difluorophenyl)-1,2-dihydro-1,2,4,5-tetrazine [prepared in the preceding step c.)] in 2 ml of glacial acetic acid at room temperature with stirring. The progress of the reaction is followed by thin layer chromatography (TLC). The reddish-violet crystals are filtered, washed with water until neutral and dried to give 0.59 g of the crystalline title product, i.e. the title compound of Example 1. This crude product is recrystallized from a mixture of petroleum ether and acetone, m.p.: 168 °C. Analysis: C(%) H(%) N(%) calculated: 48.16 2.02 16.05 found 48.23 1.94 16.07 1 H-NMR (CDCl 3 ), ppm 7.16 - 7.26, 2H, t, 3- and 5-proton of Ar(2,6-F 2 ) 7.47 - 7.51, 1H, t, 4-proton of Ar(2-Br) 7.57 - 7.61, 1H, 5-proton of Ar(2-Br) 7.63, 1H, m, 4-proton of Ar(2,6-F 2 ) 7.83, 1H, d, 3-proton of Ar(2-Br) 8.05, 1H, d, 6-proton of Ar(2-Br) 13 C-NMR (CDCl 3 ), ppm Ar(2-Br): 1 132.95 Ar(2,6-F): 1 ∼114 2 122.08 2,6 159.45, 162.00 3 132.64 3,5 112.02, 112.27 4 132.14 4 133.68 5 127.77 6 132.16 Example 2 3,6-Bis(2,6-difluorophenyl)-1,2,4,5-tetrazine a.) N,N'-Bis(2,6-difluorobenzoyl)hydrazine 9.05 g of 2,6-difluorobenzoyl chloride and a solution of 2.17 g of sodium hydroxide in 7.5 ml of water are simultaneously dropped into a solution of 1.25 g of hydrazine hydrate in 25 ml of water with stirring and cooling by ice-water. After the addition, the white suspension is stirred at room temperature for 2 hours. After filtration the solid product is washed with water and recrystallized from glacial acetic acid to yield 6.3 g of the title product as white crystals. Analysis: C(%) H(%) N(%) F(%) calculated: 53.84 2.56 8.97 24.35 found 53.67 2.46 8.97 24.15 1 H-NMR (DMSO), ppm 7.24-7.67, 6H, m, Ar 11.00, 2H, s, NH 13 C-NMR (DMSO), ppm CO NH 158.55 Ar (2,6-F 2 ) 1 113.12 2 , 6 157.86, 159.80 3 , 5 112.01 4 132.60 IR (KBr) ν C=O = 1640 cm -1 MS M(+) = 312 m/z. b.) Bis[chloro-(2,6-difluorobenzylidene)]hydrazine To a mixture containing 12.5 g of phosphorus pentachloride and 25 ml of carbon tetrachloride, 2 g of N,N'-bis(2,6-difluorobenzoyl)hydrazine [prepared in the preceeding step a.)] are portionwise added during 5 minutes while boiling under reflux. After boiling the reaction mixture under reflux for 8 hours carbon tetrachloride and phosphorus oxychloride are evaporated under reduced pressure. After adding ice-cold 10 % sodium hydroxide solution, the residue is taken up in ethyl acetate, washed with water until neutral and evaporated. The crude product obtained is purified by column chromatography. By using a 10:1 mixture of petroleum ether and acetone as eluent, 0.9 g of the title product is obtained in the form of white crystals, m.p.: 142-147 °C. Analysis: C(%) H(%) N(%) Cl(%) F(%) calculated 48.16 1.73 8.03 20.31 21.77 found 47.93 1.38 8.06 19.7 20.73 1 H-NMR (acetone-D 6 ), ppm Ar (2,6-F 2 ) 4 7.75 (m) 3 , 5 7.29 (m) IR (KBr) ν C=N = 1630 cm -1 MS M (+) = 348 m/z 13 C-NMR (acetone-D 6 ), ppm Ar (2,6-F 2 ) 1 113.29 2 , 6 158.79, 161.34 3 , 5 111.86, 112.08 4 132.50 c.) 3,6-Bis(2,6-difluorophenyl)-1,2-dihydro-1,2,4,5-tetrazine To a solution of 0.9 g of bis[chloro-(2,6-difluorobenzylidene)]hydrazine [prepared in the preceeding step b.)] in 18 ml of tetrahydrofuran, 0.59 ml of hydrazine hydrate is dropped during 1 min at 40 °C. After filtering the precipitate is washed with water and dried to give 0.5 g of the title product as yellow crystals. d.) 3,6-Bis(2,6-difluorophenyl)-1,2,4,5-tetrazine A solution of 0.12 g of sodium nitrite in 1 ml of water is added dropwise to a suspension of 0.4 g of 3,6-bis(2,6-difluorophenyl)-1,2-dihydrol-1,2,4,5-tetrazine [prepared in the preceding step c.)] in 2.5 ml of glacial acetic acid at room temperature while stirring. The progress of the reaction is followed by thin layer chromatography. After filtration the carmine crystals are washed with water until neutral to give 0.34 g of the title product. This crude product is recrystallized from a mixture of petroleum ether and acetone to give 0.251 g of pure title product of Example 2, m.p.: 213.5 °C. Analysis: C(%) N(%) H(%) F(%) calculated: 54.91 18.30 1.97 24.82 found 55.09 18.34 1.82 25.00 1 H-NMR (CDCl 3 ), ppm 7.15 - 7.21, 4H, t, 3- and 5-protons of aromatic rings 7.58 - 7.65, 2H, m, 4-protons of aromatic rings 13 C-NMR (CDCl 3 ), ppm Ar (2,6-F 2 ) 3 , 5 112.45 2 , 6 161.08 ( 1 J CF = 256.5 Hz) 4 133.72 1 111.52 Example 3 3-(2-Chlorophenyl)-6-(2,6-difluorophenyl-1,2,4,5-tetrazine a.) N-(2-Chlorobenzoyl)-N'-(2,6-difluorobenzoyl)-hydrazine Step a.) of Example 1 is followed, except that 2 g of (2-chlorobenzoyl)hydrazine are used as starting substance instead of (2-bromobenzoyl)hydrazine to give 2.03 g of white, crystalline title product. Analysis: C(%) H(%) N(%) Cl(%) F(%) calculated 54.12 2.92 9.02 11.41 12.23 found 53.85 2.86 9.05 11.05 11.63 1 H-NMR (DMSOD 6 ), ppm 7.25-7.63, 7H, m, Ar 10.71, 1H, s, Cl NH; 10.91, 1H, s, F NH b.) Step b.) of Example 1 is followed, except that the product prepared in the preceding a.) is portionwise added to a solution of phosphorus pentachloride in carbon tetrachloride. After recrystallization of the obtained product from a mixture of methanol and ethyl acetate, 1.26 g of white crystalline title product are obtained, m.p.: 85-92 °C. Analysis: C(%) H(%) N(%) Cl(%) F(%) calculated 48.37 2.03 8.06 30.6 10.93 found 48.40 1.74 7.90 30.3 10.79 1 H-NMR (CDCl 3 ), ppm 6.99-7.67, 7H, m, Ar 13 C-NMR (CDCl 3 ), ppm Ar (2-Cl): 1 131.68 Ar (2,6-F 2 ): 1 113.47 2 132.71 2, 6 158.76, 161.3 3 131.68 3 , 5 111.79, 112.0 4 130.79 4 132.53 5 130.49 6 126.80 IR (KBr) ν C=N = 1627 cm -1 c.) Step c.) of Example 1 is followed. The crude product is oxidized without purification. d.) The process described in Example 1 is followed. After recrystallization of the pale violet product from ethyl acetate 0.7 g of pure title product of Example 3 is obtained, m.p.: 184.5 °C. Analysis: C(%) H(%) N(%) Cl(%) F(%) calculated 55.19 2.32 18.39 11.64 12.47 found 55.05 2.19 18.28 10.94 12.22 1 H-NMR (CDCl 3 ), ppm 7.14 - 7.20, 2H, t, 3- and 5-protons of Ar(2,6-F 2 ) 7.51 - 7.66, 4H, m, 4,5,6-protons of Ar(2-Cl) and 4-proton of Ar(2,6-F 2 ) 8.0 - 8.11, 1H, dd, 3-proton of Ar(2-Cl) 13 C-NMR (CDCl 3 ), ppm Ar (2,6-F 2 1 111.58 2 , 6 159.71, 162.26 3 , 5 112.20, 112.45 4 133.50 Ar (2-Cl) 1 131.34 2 133.89 3 132.74 4 131.21 5 127.33 6 132.88 IR (KBr) ν C=N = 1390 cm -1 (the N atoms are in aromatic heterocycle) Reference Example 1 3,6-Bis(2-chlorophenyl)-1,2,4,5-tetrazine Steps a.), b.), c.) and d.) of Example 2 are followed, except that 2-chlorobenzoyl chloride is used in step a.) instead of 2,6-difluorobenzoyl chloride. Thus, 0.7 g of deep violet crystalline title compound is obtained, m.p.: 179-182 °C, which is identical in all respects with the target product of Example 14 of the published European patent application No. 5912. Reference Example 2 3-(2-Chlorophenyl)-6-(2-bromopbenyl)-1,2,4,5-tetrazine Example 1 is followed by using in step a.) 2 g of 2-(chlorobenzoyl)hydrazine instead of 2-(bromobenzoyl)-hydrazine and 2.7 g of 2-bromobenzoyl chloride instead of 2,6-difluorobenzoyl chloride. Thus, 0.6 g of reddish-violet crystalline title compound is obtained, m.p.: 168-170 °C, which is identical in all respects with the target product of Example 17 of EP-A-5912. Analysis: C(%) H(%) N(%) calculated: 48.37 2.32 16.12 found 47.40 2.18 15.40. 1 H-NMR (CDCl 3 ), ppm 8.10 - 8.13, 1H, dd, 6-protons of Ar(2-Br) 8.06 - 8.08, 1H, dd, 6-protons of Ar(2-Cl) 7.83 - 7.85, 1H, dd, 3-protons of Ar(2-Br) 7.46 - 7.61, 1H, m, Ar(2-Cl) Reference Example 3 3,6-Bis(2-chlorophenyl)-1,2-dihydro-1-methyl-1,2,4,5-tetrazine a.) N,N'-Bis(2-Chlorobenzoyl)hydrazine Into a flask equipped with thermometer and bubbler, 0.7 g (0.014 mol) of hydrazine hydrate and 4 ml of water are weighed. In another flask 1.2 g (0.03 mol) of sodium hydroxide are dissolved in 5 ml of water. The sodium hydroxide solution and 5 g (0.028 mol) of 2-chlorobenzoyl chloride are simultaneously added to the solution of hydrazine hydrate at such a rate that the temperature remains below 20 °C (cooling with water). A white precipitate appears. After stirring for additional 2 hours the white precipitate is filtered, washed with water and dried to give 5.04 g (57 %) of title product, m.p.: 218 °C after recrystallization from acetic acid. b.) Bis(alpha,2-dichlorobenzylidene)hydrazine To a boiling solution of 10.5 g (0.05 mol; 2.5 equivalents) of phosphorus pentachloride in 50 ml of carbon tetrachloride, 3.1 g (0.01 mol) of solid N,N'-bis(2-chlorobenzoyl)hydrazine are portionwise added. The boiling under reflux is continued until the starting substance is consumed according to thin layer chromatography (about 5 hours). For developing the TLC an 1:2 mixture of petroleum ether and acetone is used. The product obtained is poured into a mixture of 50 g of ice and 50 ml of water, then stirred with 100 ml of methylene chloride. After separation the organic phase is washed with distilled water, dried and evaporated. The crude product obtained is recrystalliized from methanol to give 1.43 g (41 %) of title compound, m.p.: 102 °C. c.) 3,6-Bis(2-chlorophenyl)-1,2-dihydro-1-methyl-1,2,4,5-tetrazine A suspension containing 3.74 g (0.026 mol) of methylhydrazine sulfate, 11.9 ml (0.086 mol) of triethylamine in 11.2 ml of abs. ethanol is boiled under reflux while portionwise adding 1.12 g (0.0032 mol) of bis(alpha,2-dichlorobenzylidene) hydrazine. The reaction mixture is kept boiling under reflux for additional 2 hours with stirring. After taking up the product in ethyl acetate, it is washed with water, dried and evaporated. A TLC analysis is carried out using an 1:2 mixture of petroleum ether and acetone as developing system. The crude product weighing 0.90 g obtained is purified by column chromatography with a 3:1 mixture of petroleum ether and acetone as eluent. Thus, 0.48 g (48 %) of the title compound is obtained, which is in complete agreement with the product described in Example 1 of the published European patent application No. 5912. 1 H-NMR (DMSOD 6 + D 2 O), ppm 9.00, 1H, s, NH 7.37-7.58, 8H, m, Ar protons 2.68-2.71, 3H, s, Me Reference Example 4 3-(2-chlorophenyl)-6-(2-bromophenyl)-1,2-dihydro-1-(or -2-)-methyl-1,2,4,5-tetrazine a.) N-(2-Chlorobenzoyl)-N'-(2-bromobenzoyl)hydrazine 2.7 g of o-bromobenzoyl chloride are added dropwise to a solution of 2 g of (2-chlorobenzoyl)hydrazine in 2 ml of dimethylformamide and 1 ml of pyridine with cooling. The suspension obtained is stirred at room temperature for additional 30 minutes, and then poured into water. The white crystalline precipitate is filtered and dried to obtain 2.95 g of white crystalline title compound. b.) Step b.) of Reference Example 3 is followed. After purifying the crude product by chromatography, 0.57 g of the title compound of Reference Example 4 is obtained which is in complete agreement with the compound described in Example 13 of EP-A-5912. 1 H-NMR (CDCl 3 ), ppm 7.26 - 7.65, 9H, m, aromatic protons and NH 3.00, 3H, s, Me Formulation Example 1 Wettable powders Wettable powder compositions of 10, 20 or 50 %, respectively are prepared from the active ingredients described in Examples 1, 2 or 3, respectively, by using 5 % of wetting and dispersing agent as well as 85, 75 or 45 %, respectively of kaolin, based on the mass of the composition. Formulation Example 2 Suspension concentrates Aqueous suspension concentrates are prepared, which contain 10, 20 or 50 %, respectively, of active ingredient described in Example 1, 2 or 3, respectively, as well as 0.2 to 2 % of xanthan gum, 5 to 10 % of surface active agent and water, based on the mass of the composition. Useful surface active substances may be lignin-sulfonate, ethoxylated fatty alcohol sulfates, alkylaryl sulfonates, salts of sulfonated phenol-formaldehyde-condensates, alkaline metal salts of ethoxylated citric acid, ethoxylated tartaric acid, ethoxylated citric/tartaric acid; triethylamine salts, of citric/tartaric acid, sodium oleoyl-N-methyltauride, dialkyl sulfosuccinates, ethoxylated alkylphenols or ethoxylated fatty alcohols. Formulation Example 3 Emulsifiable concentrates Emulsifiable concentrates, which contain 5, 10 or 20 %, respectively, by mass of the active ingredients described in Example 1, 2 or 3, respectively, and any of the surface active agents defined in Formulation Example 2 in an amount of 1 to 5 % by mass, based on the mass of the composition, as well as mixtures of aliphatic or aromatic hydrocarbons as solvents in amounts supplementing the mass of the compositions up to 100 %, are prepared. Biological Example 1 Immersion ovicidal test on spider mite (Tetranychus urticae) by using active compounds Four adult female spider mites (Tetranychus urticae WHO sensitive strain) were placed on each leaf disk of 15 mm in size cut out of young bean leaves. After egg deposition lasting 24 hours at 26 to 28 °C the females were removed, and the eggs deposited on the disks were counted. The treatments were carried out by immersing the leaf disks into solutions containing appropriate concentrations of the active compounds (by using acetone as co-solvent in an amount of not higher than 5 % in the test solution). The immersion lasted 5 seconds. After treatment, the disks were dried on dry filter paper, then maintained on wet filter paper at a temperature of 26 to 28 °C in a Petri dish until hatching out of the untreated control eggs, and the hatching out was determined. Each experiment was carried out with four repetitions by using at least three parallel tests for each concentration. The effectivity values given for each concentration show the average of treatments performed on at least 250 mite eggs. The corrected mortality was calculated according to Abbott by using the following formula: Corrected mortality (%)= observed mortality minus control mortality (%) 100 minus control mortaliy (%) The results expressed as percentages are shown in Table 1. Concentration Compounds tested according to No. of Example Ref. Ex. 4. Ref. Ex. 3. Ref. Ex. 2. Ref. Ex. 1 Example 3 Mortality % (Abbott) 0.06 0.5 3.6 1.0 1.8 19.0 0.12 1.5 5.0 15.9 20.6 60.0 0.25 5.0 7.1 41.7 59.2 94.3 Biological Example 2 Translaminar ovicidal test on spider mite (Tetranychus urticae) by using active compounds The upper side of leaves of 7 days old bean plants was treated in such a way that the bean leaf was laid with its upper side on the mouth of a glass cylindre of 20 ml in volume containing 10 ml of test solution and exposed in an overturned position for 5 seconds. Then, the leaf was taken away from the glass cylindre and laid onto a wet, multilayer paper wadding in a Petri dish. The Petri dishes were kept at a temperature between 26 and 28 °C at a relative humidity of 60 to 70 % with a light/dark cycle ratio of 16:8 under a light intensity of 1600 lux. After 24 hours, disks of 15 mm in diameter were cut out of the treated surfaces, egg-deposition was performed on the untreated sides, and then the experiment was continued as described in Biological Example 1. The results expressed as percentages are shown in Table 2. Concentration (ppm) Compounds tested according to No. of Example Ref. Ex. 1 Ex. 2 Ex. 3 Mortality % (Abbott) 400 18.9 100 100 200 18.3 100 100 100 11.4 100 100 50 7.7 100 95.8 20 4.7 84.8 91.8 10 0.0 71.3 66.7 5 - 40.1 24.9 Biological Example 3 Transovarian test on spider mite (Tetranychus urticae) by using active compounds Four adult female mites (Tetranychus urticae) for each dose were placed on a bean leaf disk treated as described in Biological Example 1 to feed the mites for 48 hours. Then, the mites were let to lay eggs on an untreated disk for 7 hours, the adults were removed,and the eggs were counted. The disks were kept in a Petri dish on wet filter paper at a temperature between 26 and 28 °C until hatching out of the untreated control eggs, and the hatching out ratio was determined. Each experiment was carried out with four repetitions with at least three parallel tests for each concentration. The effectivity values given for each concentration represent the average of treatments performed on at least 120 mite eggs. The results expressed in percentages are shown in Table 3. Concentration (ppm) Compounds tested according to No. of Example Ref. Ex. 1 Ex. 2 Ex. 3 Mortality % (Abbott) 100 35.3 90.2 80.5 50 11.3 88.8 63.2 10 6.6 61.6 44.8 Biological Example 4 Ovicidal test on spider mite (Tetranychus urticae) by using compositions The ovicidal effectivity of the 200 SC formulation prepared from the compound of Example 2 according to the Formulation Example 1 was tested as described in Biological Example 1. The results are Shown in Table 4. The concentrations relate to the active compound. Concentration (ppm) Apollo R 50 SC 200 SC Mortality % (Abbott) 0.25 44.6 95.7 0.125 36.8 82.4 0.0625 18.5 62.1 Biological Example 5 Translaminar ovicidal test on spider mite (Tetranychus urticae) by using compositions The translaminar effectivity of the 200 SC formulation prepared from the compound of Example 3 according to the Formulation Example 2 was tested as described in the Biological Example 2. The results are shown in Table 5. Concentration (ppm) Apollo R 50 SC Sanmite R 15 EC 200 SC Mortality % (Abbott) 400 20 20 100 200 20 20 100 100 20 10 100 50 10 10 100 25 10 10 96.8 12.5 10 10 84.5 6.25 10 10 54.7 pyridaben = 2-tert-butyl-5-(4-tert-butyl-benzylthio)-4-chloro-pyridazin-3(2H)-one Biological Example 6 Ovicidal effectivity on the itch-mite (Psoroptes cuniculi) From the scabs of ears of infected rabbbits smaller pieces containing 50 to 100 itch-mite eggs were separated, immersed into the appropriate test solution and incubated at 34 °C for 48 hours. (At this time the ratio of hatching out of the untreated controls exceeded 90 %.) Ethoxyethanol was used as co-solvent (in a concentration of not higher than 1 % in the test solution). After 48 hours the unhatched eggs were counted, and the effectivity of treatments was expressed as percentage of the control. The effectivity of the active compound described in Example 3 and some anti-ectoparasitic compositions being important from the veterinary medicinal point of view expressed in percentages are shown in Table 6. Active compound Composition Concentration 1000 ppm 500 ppm Mortality % Lindane - 25.6 9.5 Amitraz Mitac R 18.7 0 Phoxim Sebacil R 19.3 0 Diazinon Neocidol R 15.4 2.4 Compound of Example 3 - 89.1 52.5 Chemical names: Lindane: 1,2,3,4,5,6-hexachlorocyclohexane Amitraz: N,N'-[(methylimino)-dimethylidene]-di(2,4-xylidine) Phoxim: O,O-diethyl α-(cyanobenzylidene)amino(oxyphosphorothioate) Diazinon: O,O-diethyl-O-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate

Claims: 3,6-Disubstituted-1,2,4,5-tetrazine derivatives of formula I, wherein are: X fluorine, chlorine or bromine, and Y hydrogen or fluorine. Tetrazine derivative according to claim 1, which is 3-(2-Bromophenyl)-6-(2,6-difluorophenyl)-1,2,4,5-tetrazine. Tetrazine derivative according to claim 1, which is 3,6-Bis(2,6-difluorophenyl)-1,2,4,5-tetrazine. Tetrazine derivative according to claim 1, which is 3-(2-Chlorophenyl)-6-(2,6-difluorophenyl)-1,2,4,5-tetrazine. A method for the preparation of 3,6-disubstituted-1,2,4,5-tetrazine derivatives according to one of claims 1 to 4, characterized by reaction of a substituted bis-azine of formula II, wherein X and Y are as defined in claim 1, and A and B independently are cleavable (leaving) groups, with hydrazine of formula III H 2 N - NH 2 or the hydrate thereof, and oxidation of the obtained 3,6-disubstituted 1,2-dihydro-1,2,4,5-tetrazine of formula IV, wherein X and Y are as defined above, to obtain the compound of formula I. The method according to claim 5, characterized in that a compound of formula II is used wherein A and B are halogen, cyano or C 1-4 -alkoxy. A method for the preparation of 3,6-disubstituted 1,2,4,5-tetrazine derivatives according to one of claims 1 to 4, characterized by reaction of a 1,3,4-thiadiazole derivative of formula V, wherein X and Y are as defined in claim 1, with an alkyl sulfate of formula VII R 2 SO 4 , wherein R represents a C 1-4 -alkyl group, reaction of the obtained thiadiazolium salt of formula VI, wherein X, Y and R are as defined above, with hydrazine of formula III H 2 N - NH 2 or the hydrate thereof, and oxidation of the resulting 3,6-disubstituted 1,2-dihydro-1,2,4,5-tetrazine of formula IV, wherein X and Y are as defined above, to obtain the compound of formula I. A method for the preparation of 3,6-disubstituted 1,2,4,5-tetrazine derivatives according to one of claims 1 to 4, characterized by oxidation of a 3,6-disubstituted 1,2-dihydro-1,2,4,5-tetrazine derivative of formula IV, wherein X and Y are as defined in claim 1 to obtain the compound of formula I. Acaricidally, larvicidally and ovicidally active compositions, comprising 0.5 to 99 % by mass of one or more tetrazine derivatives of formula I according to one of claims 1 to 4 together with one or more carriers, diluting agents, fillers and/or surface active agents. Ovicidally active compositions with translaminar or transovarian effect according to claim 9, which comprise the compound according to claim 2 and/or claim 3 and/or claim 4. A method for diminishing the number of mites as well as larvae and eggs thereof, which comprises applying an effective amount of one or more compounds of formula I according to one of claims 1 to 4 or a composition according to claim 9 or 10, to a locus infected by mites or larvae or eggs thereof or to a locus exposed to such infection except to the human or animal body. A method for the preparation of acaricidally, larvicidally and ovicidally active compositions, which comprises mixing one or more tetrazine derivatives of formula I according to claim 1 to 4, with one or more suitable carriers, diluting agents, fillers and/or surface active agents.

Inventors: BLEICHER EDIT, BOTAR SANDOR DR, HAJIMICHAEL JANIS, MARMAROSI NEE KELLNER KATALIN, ORI JANOS, PAP LASZLO DR, SZEKELY ISTVAN DR, BLEICHER, EDIT, BOTAR, SANDOR, DR., HAJIMICHAEL, JANIS, MARMAROSI NEE KELLNER, KATALIN, ORI, JANOS, PAP, LASZLO, DR., SZEKELY, ISTVAN, DR., Botár, Sándor, Dr., Mármarosi née Kellner, Katalin, Ori, János, Pap, Lászlo, Dr., Székely, István, Dr.
Applicants: CHINOIN GYOGYSZER ES VEGYESZET, CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.
Application year: 1994
Main classification: C07D257
IPC codes: A01N43, C07D257, A01P7